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with PD. Compared to drug treatment, however, the ex-
penditures associated with DBS-STN are increased when
only direct costs are considered over a one year horizon.
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OBJECTIVES: to determine whether Alzheimer’s disease
patients prescribed donepezil concurrently with an inter-
acting drug will have higher hospitalization rates than
those not on donepezil.
METHODS: 1999 MEDSTAT Marketscan data was used
to obtain subject information. Of 2955 Alzheimer’s patients
included in this study, 1674 received donepezil and 1281 pa-
tients did not. Mean patient age was 79.6 years and 37.9
percent of these patients were male. Multivariable logistic re-
gression was used to isolate the impact of drug interactions
with donepezil on the propensity to incur a hospitalization.
RESULTS: Each of ten interacting drugs increased the
probability of hospitalization when taken with donepezil.
These interacting effects were particularly large for ranit-
idine, which increased hospitalization by 22%, haloperi-
dol by 18%, diltiazem by 9%, and ciprofloxacin by 9%.
These interactions raised the expected costs of hospital-
ization substantially as well.
CONCLUSION: This research strongly suggests that
drug interactions with donepezil pose significant risk for
hospitalization in Alzheimer’s patients.
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OBJECTIVE: The total cost of secondary stroke has not
been well established. The high risk of stroke recurrence,
reaching almost 50% in the first five years following pri-
mary stroke, can be substantially reduced with effective
preventive health-care programs. Thus secondary preven-
tion can produce substantial clinical benefits and eco-
nomic savings. We evaluated health-care resource use
and indirect costs in a sample population of patients after
secondary stroke.
METHODS: 2nd Neurological Department clinical data-
base was reviewed and 105 secondary stroke patients
evaluated. Life expectancy was estimated using the Kaplan-
Meier method along with a parametric hazard function
estimator. Survivors were surveyed on health-care re-
source consumption within the previous year and indirect
costs including care time at home and employment sta-
tus. Average total cost and 95% bootstrap confidence in-
tervals were calculated. This survey was aimed at evalu-
ating patient’s eventual disability with the Barthel ADL
Index. The relationship between ADL score and the total
cost of secondary stroke was determined.
RESULTS: Life expectancy for a Polish patient experi-
encing a secondary stroke was found to be 3.9 years
(95%CI: 2.25 - 5.71). Average lifetime costs for second-
ary stroke totaled 52 181 USD (95%CI: 43536–61602)
(PPP 2000). The direct costs were estimated at 24,099
USD and productivity loss due to morbidity amounted to
34.3% of the total indirect cost, while the remaining
65.7% corresponded to patient home-care costs. It was
found that the total cost decreased as ADL increased.
CONCLUSION: The costs of secondary stroke are sub-
stantial in Poland mainly due to indirect costs. Studies of
the cost of primary stroke are needed to extract the precis
cost of secondary stroke. Effective secondary prevention
can produce economic savings as a result of limiting the
burden of secondary stroke.
PND6
ASSESSING THE COSTS OF PARKINSON’S 
DISEASE IN GERMANY
Spottke AE1, Reuter M1, Smala A2, Berger K2, Athen O3, 
Köhne-Volland R3, Meyer D3, Oertel WH1, Dodel RC1
1Philipps-University Marburg, Marburg, Germany, 2 MERG - 
Medical Economics Research Group, Munich, Germany, 3 
Metronomia, Munich, Germany
OBJECTIVE: To evaluate the direct costs due to Parkin-
son’s Disease (PD) in Germany.
METHODS: Using a prospective study design we evalu-
ate the health-care utilization and health-related quality
of life of 160 patients with PD in different Hoehn and
Yahr stages (HY) over a two year period in Germany
(2000–2002). Here we present a subanalysis of consecu-
tive 34 patients (mean age: 65.2  10.5) observed for a
three-month period. Costs were derived from different
German medical economic resources and determined
from the perspective of the health care provider.
RESULTS: The mean 3-month direct costs were DM
11300. DM 10000 were costs for medical treatment and
DM 1300 for non-medical services (e.g. social services,
meals on wheels, etc.). The drug costs were the major
cost-factor with DM 8940, mainly for the use of newer
compounds like dopamine agonists and COMT-inhibi-
tors. The use of subcutaneous apomorphine in advanced
stages of the disease considerably increased the costs of
treatment (DM 6400). Hospitalization, physician care
and vindication amounted to DM 1060. Direct costs in-
creased depending on the extent of the disease (HY I:
DM 2080, HY V: DM 8840). Further cost-driving fac-
tors include the occurrence of dyskinesias and motor
fluctuations. The drug and hospitalization costs are espe-
